1
|
St-Georges J, Alnoman A, Badeghiesh A, Baghlaf H. Pregnancy, delivery, and neonatal outcomes among women with beta-thalassemia major: a population-based study of a large US database. Arch Gynecol Obstet 2025; 311:1343-1349. [PMID: 39825900 PMCID: PMC12033207 DOI: 10.1007/s00404-024-07908-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Accepted: 12/17/2024] [Indexed: 01/20/2025]
Abstract
PURPOSE We explored the effect of beta-thalassemia major on pregnancy and delivery outcomes in non-endemic area, utilizing USA population database. METHODS This is a retrospective study utilizing data from the Healthcare Cost and Utilization Project-Nationwide Inpatient Sample. A cohort of all deliveries between 2011 and 2014 was created using ICD-9 codes. The patients with beta-thalassemia major were identified and matched to patients without beta-thalassemia based on age, race, income quartile, and type of health insurance at a ratio of 1:20. The baseline characteristics were compared between the groups using Chi-square and Fischer's exact tests, as appropriate. The univariate and multivariate analyses were conducted for pregnancy, delivery and neonatal outcomes to estimate the unadjusted and adjusted odds ratio, respectively. RESULTS Out of 3,070,656 pregnancies over the study period, beta-thalassemia major complicated 445 pregnancies. The patients with beta-thalassemia were more likely to have thyroid disorders and previous C-section (p-value < 0.05). There were no differences in pregnancy outcomes such as gestational hypertension, preeclampsia, gestational diabetes, and placenta previa. C-section was 30% more likely to be the method of birth (aOR 1.30, 95%CI 1.03-1.63) and there was more than three-fold increase in rate of blood transfusion (aOR 4.69, 95% CI 3.02-7.28) among participants with beta-thalassemia major. Mothers with beta-thalassemia, almost, were 70% more likely to have a neonate small for gestational age (aOR 1.68, 95%CI 1.07-2.62). CONCLUSIONS Women with beta-thalassemia major are more likely to give birth by C-section, require blood transfusion and have small for gestational age neonates. Counseling patients with beta-thalassemia about these risks and increased antenatal surveillance is advised.
Collapse
Affiliation(s)
- Juliette St-Georges
- Department Obstetrics and Gynecology, Université de Montréal, Montréal, Canada.
| | - Abdullah Alnoman
- Department Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ahmad Badeghiesh
- Department of Obstetrics & Gynecology, King Abdulaziz University Rabigh Branch, Rabigh, Saudi Arabia
| | - Haitham Baghlaf
- Department of Obstetrics & Gynecology, University of Tabuk, Tabuk, Saudi Arabia
| |
Collapse
|
2
|
Cai A, Liu X, Ma Q, He G, Jing C, He J, Zeng F, Zhu B. Prevalence, mutation distribution, and economic burden of thalassemia in China: a systematic review and regional analysis. Arch Public Health 2025; 83:92. [PMID: 40188329 PMCID: PMC11972477 DOI: 10.1186/s13690-025-01575-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2024] [Accepted: 03/24/2025] [Indexed: 04/07/2025] Open
Abstract
BACKGROUND Thalassemia poses a significant public health and economic challenge in China. Comprehensive data on its epidemiology, mutation spectrum, and economic impact are critical for improving prevention and treatment. METHODS This systematic review, adhering to PRISMA guidelines, analyzed studiesP{lea published between 1987 and 2024 from PubMed, FMRS, and CNKI. Data from 29 eligible studies, covering 679,697 individuals across 17 regions, were standardized using next-generation sequencing benchmarks. RESULTS The national carrier rate was 8.95%, with -SEA and βCD41-42 mutations most prevalent, particularly in Hainan and Guangxi. Thalassemia contributes an annual economic burden of 9.19 billion RMB and approximately 3,590 stillbirths in the absence of prevention programs. CONCLUSIONS While regional screening has reduced incidence since 1987, the disease continues to strain China's healthcare system. These findings highlight the pressing need to expand national prevention programs to mitigate its health and economic impacts. Insights from this review are vital for shaping public health strategies in high-prevalence areas.
Collapse
Affiliation(s)
- Aiqi Cai
- Faculty of Life Science and Technology, Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China
- Department of Medical Genetics, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, the First People'S Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China
| | - Xiaohu Liu
- Department of Medical Genetics, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, the First People'S Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China
| | - Qingwen Ma
- Shanghai Children'S Hospital, Shanghai Institute of Medical Genetics, Shanghai Jiao Tong University School of Medicine, 24/1400 West Beijing Road, Shanghai, 200040, China
- NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology, Shanghai Key Laboratory of Embryo and Reproduction Engineering, 24/1400 West Beijing Road, Shanghai, 200040, China
| | - Guangyu He
- Department of Medical Genetics, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, the First People'S Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China
| | - Chanchan Jing
- Department of Medical Genetics, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, the First People'S Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China
| | - Jing He
- Faculty of Life Science and Technology, Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China
- Department of Medical Genetics, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, the First People'S Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China
| | - Fanyi Zeng
- Shanghai Children'S Hospital, Shanghai Institute of Medical Genetics, Shanghai Jiao Tong University School of Medicine, 24/1400 West Beijing Road, Shanghai, 200040, China.
- Department of Histo-Embryology, Genetics and Developmental Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology, Shanghai Key Laboratory of Embryo and Reproduction Engineering, 24/1400 West Beijing Road, Shanghai, 200040, China.
| | - Baosheng Zhu
- Faculty of Life Science and Technology, Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China.
- Department of Medical Genetics, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, the First People'S Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China.
- NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology, Shanghai Key Laboratory of Embryo and Reproduction Engineering, 24/1400 West Beijing Road, Shanghai, 200040, China.
| |
Collapse
|
3
|
Petrukhina D, Musina N, Slavkina Y, Latypova V, Zemlyanaya N, Saprina T. Incidence of carbohydrate metabolism disorder in iron overload of different etiology. RUSSIAN JOURNAL OF PREVENTIVE MEDICINE 2024; 27:111. [DOI: 10.17116/profmed202427051111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2025]
|
4
|
Zhang W, Han X, Deng J, Zhou R, Du X, Wu C, Li M. Two Novel α-Thalassemia Mutations CD 39 -C [Thr > Pro] and CD 109 ACC > CCC [Thr > Pro] Identified in Two Chinese Families: A Case Report. Hemoglobin 2023; 47:172-179. [PMID: 37818638 DOI: 10.1080/03630269.2023.2263365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 09/09/2023] [Indexed: 10/12/2023]
Abstract
We reported the identification of two rare α-thalassemia silent carriers with novel HBA1 mutations of CD 39 -C [Thr > Pro] (HBA1: c.114del; p.Thr39Profs*11) and CD 109 ACC > CCC [Thr > Pro] (HBA1: c.325A > C; p. Thr109Pro), respectively. The two probands were pregnant women diagnosed with mild hypochromic anemia or microcytic hypochromic anemia by routine blood tests. They started iron therapy before taking differential diagnosis from iron deficiency anemia. After wait and watch approach, they both accepted thalassemia genetic screening, which identified CD 39 -C [Thr > Pro] and CD 109 ACC > CCC [Thr > Pro], respectively. Due to inappropriate iron therapy, worse anemia and iron overload were noticed in the first proband, but no obvious side effect was found in both probands. Functional analysis showed that, relative to the wild type, CD 39 -C [Thr > Pro] considerably reduced the expression of the HBA1 protein while CD 109 ACC > CCC [Thr > Pro] only had a minor impact. Our study highlighted the importance of gestational thalassemia screening based on next-generation sequencing for identifying novel rare thalassemia variants and increased our understanding about the relationship between genotype and phenotype of α-thalassemia.
Collapse
Affiliation(s)
- Wenqian Zhang
- BGI Genomics, Shenzhen, China
- Clin Lab, BGI Genomics, Wuhan, China
- Department of Biology, University of Copenhagen, Copenhagen, Denmark
| | - Xiaoqiang Han
- Department of Obstetrics and Gynecology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China
| | - Jie Deng
- Department of Obstetrics and Gynecology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China
| | - Rui Zhou
- BGI Genomics, Shenzhen, China
- Clin Lab, BGI Genomics, Wuhan, China
| | - Xiaoyun Du
- BGI Genomics, Shenzhen, China
- Clin Lab, BGI Genomics, Wuhan, China
| | - Cheng Wu
- BGI Genomics, Shenzhen, China
- Clin Lab, BGI Genomics, Wuhan, China
| | - Mingqun Li
- Department of Obstetrics and Gynecology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China
| |
Collapse
|
5
|
Zeng X, Liu Z, He C, Wang J, Yan L. Prevalence and molecular characterization of alpha and beta-Thalassemia mutations among Hakka people in southern China. Genet Mol Biol 2022; 45:e20220043. [PMID: 36288450 PMCID: PMC9601249 DOI: 10.1590/1678-4685-gmb-2022-0043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 07/07/2022] [Indexed: 11/04/2022] Open
Abstract
Our aim was to investigate molecular features of thalassemia for proper clinical consultation and prevention in Heyuan. In our research, a total of 25,437 positive screening subjects were further subjected to a genetic analysis of α-thalassemia (α-thal) and β-thalassemia (β-thal). The deletion of α-thal mutation was tested by Gap-PCR, while the non-deletion of α-thal and β-thal mutation were identified by the PCR-reverse dot blot (PCR-RDB) technique. Nested PCR detected Hkαα/-- SEA and Hkαα/αα. Among the 25,437 positive screening subjects, 44.09% (11216/25437) subjects were bearers of thalassemia variations, and 30.85% (7847/25437) subjects showed α-thal changes alone. Among the 23 genotypes with α-thal mutation alone, the three common genotypes were --SEA/αα(68.34%), -α3.7/αα(16.44%), and -α4.2/αα(6.38%). Of the 11.50% (2924/25437) subjects and 29 genotypes with β-thal mutation alone, the three common genotypes were βCD41-42/βN(36.22%), βIVS-II-654/βN(30.88%), and β-28/βN(13.47%). Additionally, of the 1.75% (445/25437) subjects and 55 genotypes showed both α- and β-thal mutations. We also identified 269 cases of Hb H and six patients of Hkαα. Furthermore, the common genotypes of α-thal and β-thal mutations were consistent with allele frequencies of mutations. Our study establishes molecular features of thalassemia among Hakka people in Heyuan. It will be useful for developing strategies to prevent thalassemia.
Collapse
Affiliation(s)
- XiangXing Zeng
- Heyuan Women and Children's Hospital, Laboratory of Medical Genetics, Heyuan, Guangdong, China.,Heyuan Women and Children's Hospital, Department of Clinical Laboratory, Heyuan, Guangdong, China
| | - ZhiFang Liu
- Heyuan Health Supervision Institute, Department of Integrated Enforcement, Heyuan, Guangdong, China
| | - CaiHua He
- Heyuan Women and Children's Hospital, Department of Clinical Laboratory, Heyuan, Guangdong, China
| | - Jia Wang
- Heyuan Women and Children's Hospital, Laboratory of Medical Genetics, Heyuan, Guangdong, China
| | - LiXiang Yan
- Heyuan Women and Children's Hospital, Laboratory of Medical Genetics, Heyuan, Guangdong, China
| |
Collapse
|
6
|
Luo H, Huang T, Lu Q, Zhang L, Xu Y, Yang Y, Guo Z, Yuan H, Shen Y, Huang S, Yang B, Zou Y, Liu Y. Molecular prevalence of HBB-associated hemoglobinopathy among reproductive-age adults and the prenatal diagnosis in Jiangxi Province, southern central China. Front Genet 2022; 13:992073. [PMID: 36246595 PMCID: PMC9554255 DOI: 10.3389/fgene.2022.992073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 09/08/2022] [Indexed: 11/13/2022] Open
Abstract
Background and aims: Hemoglobinopathy associated with the HBB gene, with its two general subtypes as thalassemia and abnormal hemoglobin (Hb) variants, is one of the most prevalent hereditary Hb disorders worldwide. Herein we aimed to elucidate the prevalence of ß-thalassemia and abnormal hemoglobin variants and the prenatal diagnosis of the HBB gene in Jiangxi Province, southern central China.Methods: Hematological indices and capillary Hb electrophoresis were conducted for 136,149 subjects who were admitted to Jiangxi Maternal and Child Health Hospital and requested for hemoglobinopathy investigation. Routine α- and ß-globin genotyping were performed by gap-polymerase chain reaction (Gap-PCR) and reverse dot-blot (RDB) hybridization for the 11,549 individuals suspected to be thalassemia carriers. For participants whose genotypes could not explain their hematological indices, further Sanger sequencing and Gap-PCR were conducted for the detection of rare or novel variants in related globin genes. Prenatal diagnosis was performed for 77 pregnant couples both carrying ß-thalassemia trait at appropriate gestational ages.Results: Among the 11,549 subjects, 2,548 individuals were identified with HBB-associated hemoglobinopathy based on molecular analysis. A total of 2,358 subjects were identified as ß-thalassemia heterozygous carriers and nine cases were diagnosed as compound heterozygous ß-thalassemia. Additionally, 125 cases were detected with composite α- and ß-thalassemia and the remaining 56 individuals with abnormal Hb variants in the HBB. A total of 35 types of variants were identified in the HBB gene, including 26 types of ß-thalassemia and nine types of abnormal Hb variants. Four novel variants were firstly reported, including one variant in HBA2 and three variants in HBB. Overall, 77 prenatal samples underwent ß-thalassemia molecular diagnosis; 20 fetuses were identified with normal ß-thalassemia genotypes, 30 fetuses as ß-thalassemia heterozygotes, 11 as homozygotes, and 16 as compound heterozygotes in HBB.Conclusion: We have demonstrated a relatively high prevalence rate at 1.872% of ß-hemoglobinopathies including common and rare ß-thalassemia as well as abnormal Hb variants among large child-bearing population in the Jiangxi area of southern central China for the first time. Our data presents that prenatal diagnosis is an effective way to prevent and control birth defects of ß-thalassemia.
Collapse
Affiliation(s)
- Haiyan Luo
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Ting Huang
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Qing Lu
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Liuyang Zhang
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Yonghua Xu
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Yan Yang
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Zhen Guo
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Department of Ultrasound, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Huizhen Yuan
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Yinqin Shen
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Shuhui Huang
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Bicheng Yang
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Yongyi Zou
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- *Correspondence: Yongyi Zou, ; Yanqiu Liu,
| | - Yanqiu Liu
- Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- Jiangxi Key Laboratory of Birth Defect Prevention and Control, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
- *Correspondence: Yongyi Zou, ; Yanqiu Liu,
| |
Collapse
|